Finally, in patients with anti-phospholipid syndrome (APS), circulating aPL (anti-phospholipid) antibodies disrupt the anticoagulant crystallization shied of anxA5 and consequently highly promote thrombosis in the placenta and the cardiovascular system [64–67]. The gene discussed is FASLG; the disease is autoimmune polyendocrinopathy.